Development of a SARS-CoV-2 spike protein binding assay using human epithelial cells for COVID-19 therapy discovery and development

Medicine & Life Sciences

1. SARS Virus 100%
2. Antibodies 37%
3. Serum 30%
4. Proteins 24%
5. Monoclonal Antibodies 16%
6. Neutralizing Antibodies 11%
7. Recombinant Proteins 11%
8. Anti-Idiotypic Antibodies 9%
9. Fluorescence 9%
10. Tissue Donors 8%
11. Vaccines 8%
12. Infections 5%